



Silence Therapeutics to Participate in September Investor Conferences

2025-09-02

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in the following conferences:

- Morgan Stanley Global Healthcare Conference
Fireside Chat on Tuesday, September 9, 2025 at 5:35 p.m. ET
- H.C. Wainwright Global Investment Conference
Fireside Chat on Wednesday, September 10, 2025 at 12:00 p.m. ET

The webcasts can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com.

About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit <https://www.silence-therapeutics.com/>.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250902137472/en/): <https://www.businesswire.com/news/home/20250902137472/en/>

Inquiries:

Silence Therapeutics plc

Gem Hopkins, VP, Head of IR and Corporate Communications

ir@silence-therapeutics.com

Tel: +1 (646) 637-3208

Source: Silence Therapeutics plc